Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials

References

• Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A synopsis. Am J Manag Care. 2014 May;20(7 Suppl):S128–35.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017 Oct;9(10):249–262.
   PubMed Web of Science ®Google Scholar
• Yu C, Jin S, Wang Y, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019 Mar;38(3):727–738.
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007 Apr;19(2):117–123.
   PubMed Web of Science ®Google Scholar
• D’Aura Swanson C, Paniagua RT, Lindstrom TM, et al. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol. 2009 Jun;5(6):317–324.
   PubMed Web of Science ®Google Scholar
• He X, Chen X, Zhang H, et al. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018). Expert Opin Ther Pat. 2019 Feb;29(2):137–149.
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373–398.
   PubMed Web of Science ®Google Scholar
• Shah RR, Roberts SA, Shah DR. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors. Br J Clin Pharmacol. 2013 Sep;76(3):396–411.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019 Jun;144:19–50.
   PubMed Web of Science ®Google Scholar
• Lv J, Wu J, He F, et al. Development of bruton’s tyrosine kinase inhibitors for rheumatoid arthritis. Curr Med Chem. 2018;25(42):5847–5859.
   PubMed Web of Science ®Google Scholar
• Scott IC, Scott DL. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? Drugs. 2014 Mar;74(4):415–422.
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez J-B. Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases: miniperspective. J Med Chem. 2014;57(12):5023–5038.
   PubMed Web of Science ®Google Scholar
• Bousoik E, Montazeri Aliabadi H. “Do we know jack” About JAK? A closer look at JAK/STAT signaling pathway. Front Oncol. 2018;8:287.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013 Mar;9(3):173–182.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 Apr;21(1):89.
   PubMedGoogle Scholar
• Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019 Jan;46(1):7–18.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Kremer JM, Emery P, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988–995.
   PubMed Web of Science ®Google Scholar
• Harigai M, Takeuchi T, Smolen JS, et al. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials. Mod Rheumatol. 2019;20:1–8.
   Google Scholar
• Keystone EC, Genovese MC, Schlichting DE, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol. 2018 Jan;45(1):14–21.
   PubMed Web of Science ®Google Scholar
• Peterfy C, DiCarlo J, Emery P, et al. Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 2019 Jan;46(8):887–895.
   PubMed Web of Science ®Google Scholar
• Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018 Mar;20(1):57.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr;186(7):4234–4243.
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 Jan;26(1):127–132.
   PubMed Web of Science ®Google Scholar
• Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clin Ther. 2014 Jul;36(7):1074–1086.
   PubMed Web of Science ®Google Scholar
• Klunder B, Mohamed MF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018 Aug;57(8):977–988.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Kivitz AJ, Simon-Campos JA, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther. 2015;17:95.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253–1262.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Ostergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016 Jun;75(6):1024–1033.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016 Apr;75(4):687–695.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017 Oct;69(10):1969–1977.
   PubMed Web of Science ®Google Scholar
• Subesinghe S, Bechman K, Rutherford AI, et al. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol. 2018 Jun;45(6):733–744.
   PubMed Web of Science ®Google Scholar
• MacFarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014 May;17(4):359–368.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011 Feb;10(2):127–140.
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011 Dec;51(12):1644–1654.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genovese MC, Keystone E, et al. Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis. Arthritis Rheum. 2017 May;69(5):943–952.
   Web of Science ®Google Scholar
• Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016 Mar;43(3):504–511.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Ishii T, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Mod Rheumatol. 2018 Jan;28(1):20–29.
   PubMed Web of Science ®Google Scholar
• Mahajan S, Hogan JK, Shlyakhter D, et al. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 May;353(2):405–414.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2015 Feb;67(2):334–343.
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):46–55.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Yang F, Ostergaard M, et al. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann Rheum Dis. 2016 Nov;75(11):1979–1983.
   PubMed Web of Science ®Google Scholar
• Galien R, Brys R, Van der Aa A, et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK Cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib. Arthritis Rheumatol. 2015;67(Suppl 10):2781.
   Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective jak1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015 Aug;54(8):859–874.
   PubMed Web of Science ®Google Scholar
• Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials. Arthritis Rheumatol. 2017 Oct;69(10):1949–1959.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017 Jun;76(6):998–1008.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Alten R, Pavlova D, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a phase 2B dose ranging study [abstract]. Arthritis Rheumatol. 2015;67(suppl 10):1366–1367.
   Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017 Jun;76(6):1009–1019.
   PubMed Web of Science ®Google Scholar
• Hamaguchi H, Amano Y, Moritomo A, et al. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg Med Chem. 2018 Aug 4;26(18):4971–4983.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gutierrez-Urena SR, Poiley J, et al. Peficitinib, a JAK Inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017 Apr;69(4):709–719.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017 May;69(5):932–942.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016 Jun;75(6):1057–1064.
   PubMed Web of Science ®Google Scholar
• Markham A, Keam SJ. Peficitinib: first global approval. Drugs. 2019 Jun;79(8):887–891.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.
   PubMedGoogle Scholar
• Mohamed M, Camp H, Jiang P, et al. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547–1558.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT‐494, a selective JAK‐1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866.
   PubMed Web of Science ®Google Scholar
• Mascarenhas JO, Talpaz M, Gupta V, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327–335.
   PubMed Web of Science ®Google Scholar
• Luchi M, Fidelus-Gort R, Douglas D, et al. A randomized, dose-ranging, placebo-controlled, 84-day study of INCB039110, a selective Janus kinase-1 inhibitor, in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum. 2013;65(suppl):S765–S766.
   Google Scholar
• Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000 Jun;175:120–127.
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012 Apr 19;119(16):3744–3756.
   PubMed Web of Science ®Google Scholar
• Whang JA, Chang BY. Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov Today. 2014 Aug;19(8):1200–1204.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Gupta R, Valenzuela G, et al. A phase 2a, 4-week double-blind, proof-of-concept efficacy and safety study of CC-292 versus placebo as co-therapy with methotrexate in active rheumatoid arthritis (RA) [abstract]. Arthritis Rheum. 2016;68(suppl 10):1587.
   Google Scholar
• Lee J, Son J, Sin HJ, et al. THU0185 safety, pharmacokinetics and proof-of-mechanism of an oral bruton’s tyrosine kinase Inhibitor HM71224 in healthy adult volunteers. Ann Rheum Dis. 2015 Jun;74(Suppl 2):261.
   Google Scholar
• Evans EK, Tester R, Aslanian S, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219–228.
   PubMed Web of Science ®Google Scholar
• Norman P. Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2016 Aug;25(8):891–899.
   PubMed Web of Science ®Google Scholar
• Park J, Park J, Lee Y, et al. THU0499 Hm71224, a novel oral BTK inhibitor, inhibits human immune cell activation: new drug candidate to treat B-cell associated autoimmune diseases [abstract]. Ann Rheum Dis. 2014;73(suppl 2):355–356.
   Google Scholar
• Park JK, Byun JY, Park JA, et al. HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther. 2016;18:91.
   PubMed Web of Science ®Google Scholar
• Gillooly KM, Pulicicchio C, Pattoli MA, et al. Bruton’s tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. PLoS One. 2017;12(7):e0181782.
   PubMed Web of Science ®Google Scholar
• Lee SK, Xing J, Catlett IM, et al. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. Eur J Clin Pharmacol. 2017 Jun;73(6):689–698.
   PubMed Web of Science ®Google Scholar
• Schlevogt B, Kinast V, Reusch J, et al. Chronic hepatitis E virus infection during lymphoplasmacytic lymphoma and ibrutinib treatment. Pathogens. 2019 Aug;8(3):129.
   Web of Science ®Google Scholar
• Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115.
   PubMed Web of Science ®Google Scholar
• Scheers E, Leclercq L, de Jong J, et al. Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289–297.
   PubMed Web of Science ®Google Scholar
• de Jong J, Hellemans P, Jiao JJ, et al. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study. Cancer Chemother Pharmacol. 2017 Dec;80(6):1227–1237.
   PubMed Web of Science ®Google Scholar
• Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240–252.
   PubMed Web of Science ®Google Scholar
• Bradshaw JM, McFarland JM, Paavilainen VO, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol. 2015;11(7):525.
   PubMed Web of Science ®Google Scholar
• Smith PF, Krishnarajah J, Nunn PA, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017 Nov;83(11):2367–2376.
   PubMed Web of Science ®Google Scholar
• Esfandiari E, Gevorkyan H, Faessel H, et al. SAT0226 A phase 1, randomized, double-blind, placebo-controlled, single-and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers [abstract]. Ann Rheum Dis. 2018;77(suppl 2):974.
   Google Scholar
• Slomiany BL, Slomiany A. Syk: a new target for attenuation of Helicobacter pylori-induced gastric mucosal inflammatory responses. Inflammopharmacology. 2019 Apr;27(2):203–211.
   PubMed Web of Science ®Google Scholar
• Turner M, Schweighoffer E, Colucci F, et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000 Mar;21(3):148–154.
   PubMedGoogle Scholar
• Patel D, Gaikwad S, Challagundla N, et al. Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis. Int Immunopharmacol. 2018;54:375–384.
   PubMed Web of Science ®Google Scholar
• Csete D, Simon E, Alatshan A, et al. Hematopoietic or osteoclast-specific deletion of syk leads to increased bone mass in experimental mice. Front Immunol. 2019;10:937.
   PubMed Web of Science ®Google Scholar
• Abtahian F, Guerriero A, Sebzda E, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science. 2003 Jan 10;299(5604):247–251.
   PubMed Web of Science ®Google Scholar
• Jakus Z, Simon E, Balazs B, et al. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum. 2010 Jul;62(7):1899–1910.
   PubMed Web of Science ®Google Scholar
• Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010 Jun;10(6):387–402.
   PubMed Web of Science ®Google Scholar
• Kunwar S, Devkota AR, Ghimire DK. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. Rheumatol Int. 2016 Aug;36(8):1077–1087.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014 Dec;66(12):3255–3264.
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998–1008.
   PubMed Web of Science ®Google Scholar
• Martin P, Oliver S, Gillen M, et al. Pharmacokinetic properties of fostamatinib in patients with renal or hepatic impairment: results from 2 Phase I clinical studies. Clin Ther. 2015 Dec;37(12):2823–2836.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015 Dec;74(12):2123–2129.
   PubMed Web of Science ®Google Scholar
• Vollenhoven R, Cohen SB, Mease PJ, et al. Efficacy and Safety of MK-8457, a novel SYK inhibitor for the treatment of rheumatoid arthritis in two randomized, controlled, phase 2 studies [abstract]. Arthritis Rheumatol. 2014;15(suppl):S673–S674.
   Google Scholar
• Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014;57(9):3856–3873.
   PubMed Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Lee G, et al. PRT062070: a dual Syk/JAK inhibitor with potent immune regulatory capacity in rodent models of inflammation and cancer [abstract]. Blood. 2012;120(21):2764.
   Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012;340(2):350–359.
   PubMed Web of Science ®Google Scholar
• Norman P. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010-2013. Expert Opin Ther Pat. 2014 May;24(5):573–595.
   PubMed Web of Science ®Google Scholar
• Trepo C. A brief history of hepatitis milestones. Liver Int. 2014 Feb;34(suppl 1):29–37.
   PubMedGoogle Scholar
• McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017 Jun;389(10086):2328–2337.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Lee EBKaplan IV, Tofacitinib, an oral janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016 May;75(5):831–41.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017 Jun;389(10086):2328–2337. doi:10.1016/S0140-6736(17)31472-1
   PubMed Web of Science ®Google Scholar